Results 261 to 270 of about 2,496,067 (290)

00-00-14b

core  

Some of the next articles are maybe not open access.

Related searches:

JTM-00-01 NDE Acceptance Criteria for Girth Defects Linked with Welding and Inspection Technique

2001
Experimental work was conducted on two girth welds in large diameter steel pipes. By a proper selection of welding consumables, yield strength mismatch was obtained from 5 to 12% undermatching and 45% overmatching. The girth welds were non-destructively tested using the time of flight diffraction technique by three NDE companies.
W.N. Schipaunboord, M.A. Lont, A.H.M. Kron   +2 more
openaire   +1 more source

RETRACTED: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

The Lancet Oncology, 2007
We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III ...
Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD   +18 more
openaire   +3 more sources

00-01 "Still Dead After All These Years: Interpreting the Failure of General Equilibrium Theory." [PDF]

Frank Ackerman
openaire   +2 more sources

P53 functional assay in yeast: evaluation in 1856 patients in a large prospective clinical trial (EORTC 10994/BIG 00-01).

Cancer Research, 2009
Abstract Abstract #1067 Background:Although mutations in the p53 gene can occur in 20-30% of sporadic breast cancer, and are associated with other poor prognostic factors, there is no clear evidence as to whether p53 status should influence therapy.
H Bonnefoi, AS Zimmer, M Piccart, L Mauriac, M Campone, M Tubiana-Hulin, T Petit, P Rouanet, M Welnicka-Jaskiewicz, T Cufer, E Blot, V Becette, J Bogaerts, S André, D Cameron, J Bergh, R Iggo   +16 more
openaire   +1 more source

Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol

Journal of Pediatric Hematology/Oncology, 2018
Health-related quality of life (HRQL) improved progressively during therapy and beyond in children treated for acute lymphoblastic leukemia on the Dana-Farber Cancer Institute (DFCI) 95-01 protocol. This study aimed to validate that trajectory in a successor study (DFCI 00-01) and to compare the HRQL of patients in the 2 studies.
Charlene, Rae, William, Furlong, David, Feeny, Rana, Couchman, Lewis, Silverman, Stephen, Sallan, Caroline, Laverdiere, Luis, Clavell, Bruno, Michon, Kara, Kelly, Eric, Larsen, Eleanor, Pullenayegum, Uma, Athale, Ronald, Barr   +13 more
openaire   +2 more sources

Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01.

Blood, 2009
Abstract Abstract 321 BACKGROUND: The DFCI-ALL Consortium Protocol 00-01 aimed to determine the relative efficacy and toxicity of 1) dexamethasone (DEX) vs. prednisone (PRED) and 2) asparaginase (ASP) with individualized dosing (ID) based on pharmacokinetic measurements vs.
Lynda M. Vrooman, Donna S. Neuberg, Kristen E. Stevenson, Jeffrey G. Supko, Stephen E. Sallan, Lewis B. Silverman   +5 more
openaire   +1 more source

Survey of Navy Funded Marine Mammal Research and Studies FY 00-01

2001
Abstract : The enclosed report is submitted in response to your annual letter to the Office of the Assistant Secretary of the Navy for Research, Development and Acquisition, requesting information on marine mammal related research conducted or supported by the Navy in the previous fiscal year (FYOO), and planned for the current fiscal year (FYO1). Navy
openaire   +1 more source

Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01

Journal of Clinical Oncology, 2007
Purpose This randomized, double-blind, placebo-controlled phase III study aimed to determine whether thalidomide prolongs survival of patients with extensive-disease small-cell lung cancer (SCLC). Patients and Methods One hundred ...
Pujol, Jean Louis, Breton, Jean Luc, Gervais, Radj, Tanguy, Marie-Laure, Quoix, Elisabeth, David, Philippe, Janicot, Henri, Westeel, Virginie, Gameroff, Sabine, Genève, Jean, Maraninchi, Dominique   +10 more
openaire   +3 more sources

Predicting the efficacy of anthracyclines in breast cancer (BC): The results of the TOP trial and their validation in the BIG 00-01 trial.

2009
info:eu-repo/semantics ...
Desmedt, Christine, de Azambuja, Evandro, Larsimont, Denis, Haibe-Kains, Benjamin, Lallemand, Françoise, Rouas, Ghizlane, Selleslags, Jean, Delaloge, Suzette, Duhem, Caroline, Kains, Jean-Pierre, Carly, Birgit, Maerevoet, Marie, Vindevoghel, Anita, Cardoso, Fatima, Durbecq, Virginie, Nogaret, Jean-Marie, Veys, Isabelle, Schobbens, Jean, Noterman, Danièle, Salgado, Roberto, Di Leo, Angelo, D'Hondt, Veronique, Piccart-Gebhart, Martine, Sotiriou, Christos   +23 more
openaire   +1 more source